Please login to the form below

Not currently logged in

Hospira’s oncology drug approved by FDA

Hospira gains approval from the FDA for new oncology drug, gemcitabine injection

The US Food and Drug Administration (FDA) has approved a new oncology drug by Hospira.

The approval was for gemcitabine injection, a solution form of the drug. The company says that this solution form reduces preparation time and gives the medical community “access to a lower-cost, more convenient offering” of the oncology drug. 

Hospira is hoping to launch the product by early September, and will be the first company to offer gemcitabine in a solution formulation for the US market. 

The concentration of the solution is the same as the reconstituted strength of the currently available “freeze-dried” form, but will eliminate the need for reconstitution, thus improving work flow, according to the company.

Hospira hopes that it will also improve pharmacist convenience and handling safety. 

8th August 2011


Featured jobs

Subscribe to our email news alerts


Add my company

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...